Surface Engineering of Lanthanide Nanoparticles for Oncotherapy

镧系元素 纳米颗粒 光热治疗 表面改性 纳米技术 材料科学 化学 离子 物理化学 有机化学
作者
Zichao Luo,Zhigao Yi,Xiaogang Liu
出处
期刊:Accounts of Chemical Research [American Chemical Society]
卷期号:56 (4): 425-439 被引量:30
标识
DOI:10.1021/acs.accounts.2c00681
摘要

ConspectusSurface-modified lanthanide nanoparticles have been widely developed as an emerging class of therapeutics for cancer treatment because they exhibit several unique properties. First, lanthanide nanoparticles exhibit a variety of diagnostic capabilities suitable for various image-guided therapies. Second, a large number of therapeutic molecules can be accommodated on the surface of lanthanide nanoparticles, which can simultaneously achieve combined cancer therapy. Third, multivalent targeting ligands on lanthanide nanoparticles can be easily modified to achieve high affinity and specificity for target cells. Last but not least, lanthanide nanoparticles can be engineered for spatially and temporally controlled tumor therapy, which is critical for developing precise and personalized tumor therapy. Surface-modified lanthanide-doped nanoparticles are widely used in cancer phototherapy. This is due to their unique optical properties, including large anti-Stokes shifts, long-lasting luminescence, high photostability, and the capacity for near-infrared or X-ray excitation. Upon near-infrared irradiation, these nanoparticles can emit ultraviolet to visible light, which activates photosensitizers and photothermal agents to destroy tumor cells. Surface modification with special ligands that respond to tumor microenvironment changes, such as acidic pH, hypoxia, or redox reactions, can turn lanthanide nanoparticles into a smart nanoplatform for light-guided tumor chemotherapy and gene therapy. Surface-engineered lanthanide nanoparticles can include antigens that elicit tumor-specific immune responses, as well as immune activators that boost immunity, allowing distant and metastatic tumors to be eradicated. The design of ligands and surface chemistry is crucial for improving cancer therapy without causing side effects. In this Account, we classify surface-modified lanthanide nanoparticles for tumor therapy into four main domains: phototherapy, radiotherapy, chemotherapy, and biotherapy. We begin by introducing fundamental bioapplications and then discuss recent developments in tumor phototherapy (photodynamic therapy and photothermal therapy), radiotherapy, chemotherapy, and biotherapy (gene therapy and immunotherapy). We also assess the viability of a variety of strategies for eliminating tumor cells through innovative pathways. Finally, future opportunities and challenges for the development of more efficient lanthanide nanoprobes are discussed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
牛牛发布了新的文献求助10
刚刚
刚刚
zier发布了新的文献求助10
3秒前
4秒前
悬夜完成签到,获得积分10
4秒前
贪玩岱周发布了新的文献求助10
4秒前
霸气的断缘完成签到,获得积分10
8秒前
美好鞅发布了新的文献求助10
8秒前
天津中医药峰完成签到,获得积分10
11秒前
Barry完成签到,获得积分10
12秒前
14秒前
Zzzzccc发布了新的文献求助10
20秒前
21秒前
科研通AI5应助63采纳,获得10
21秒前
牛牛完成签到,获得积分10
23秒前
djf发布了新的文献求助10
25秒前
63完成签到,获得积分20
26秒前
华仔应助西西采纳,获得10
26秒前
lxd完成签到,获得积分10
27秒前
27秒前
Zzzzccc完成签到 ,获得积分10
31秒前
31秒前
ZJ发布了新的文献求助10
32秒前
ls完成签到,获得积分10
33秒前
33秒前
星辰大海应助周钰波采纳,获得20
34秒前
西西完成签到,获得积分10
35秒前
36秒前
37秒前
西西发布了新的文献求助10
37秒前
隐形曼青应助笙笙采纳,获得10
38秒前
ZJ完成签到,获得积分10
39秒前
prim发布了新的文献求助10
40秒前
归尘应助sywkamw采纳,获得30
40秒前
Singularity应助夹心吉吉采纳,获得10
41秒前
41秒前
43秒前
田様应助坦率的傲芙采纳,获得10
44秒前
机灵一兰完成签到 ,获得积分10
44秒前
李爱国应助美好鞅采纳,获得10
45秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
Mindfulness and Character Strengths: A Practitioner's Guide to MBSP 380
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3776521
求助须知:如何正确求助?哪些是违规求助? 3322010
关于积分的说明 10208485
捐赠科研通 3037297
什么是DOI,文献DOI怎么找? 1666647
邀请新用户注册赠送积分活动 797596
科研通“疑难数据库(出版商)”最低求助积分说明 757872